Satellos Bioscience to Webcast Live at VirtualInvestorConferences.com June 23rd

Author of the article: Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com TORONTO, June 20, 2022 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are…
Satellos Bioscience to Webcast Live at VirtualInvestorConferences.com June 23rd

Author of the article:

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

TORONTO, June 20, 2022 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, Founder and CEO, will present live at VirtualInvestorConferences.com on June 23, 2022 

DATE: June 23, 2022 

TIME: 11:30am ET

LINK: https://bit.ly/3LqBLWl

This will be a live, interactive online event where investors are invited to ask the company questions in real-time.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. 

Learn more about the event at www.virtualinvestorconferences.com. 

About Satellos Bioscience Inc.

Satellos is a biotechnology company dedicated to developing lifechanging medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how muscle disorders are treated. Our scientific founder, Dr. Michael Rudnicki, is a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He has shown how defects in a process known as stem cell “polarity”, which controls how muscle stem cells divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne and potentially other muscle disorders. As a result of this ongoing inability to produce sufficient numbers of new muscle cells, the muscles of people living with Duchenne are unable to keep up with and repair the continuous and accumulating damage their muscles experience. Satellos’ lead program is focused on developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore the body’s innate muscle repair and regeneration process. We believe our unique therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients. To expand our programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment. For more information about or to discuss potential collaborations with Satellos concerning our discovery platform and therapeutic candidates or our subsidiary Amphotericin B Technologies Inc., please contact Ryan Mitchell, PhD, Director – Business Development at [email protected] or visit Satellos.com.

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. 

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. 

CONTACTS:

Satellos Bioscience Inc.

Christina Cameron

Investor Relations

[email protected]

647.660.1780

Virtual Investor Conferences 

John M. Viglotti 

SVP Corporate Services, Investor Access 

OTC Markets Group 

(212) 220-2221 

[email protected]

Notice on forward-looking statements:

This press release includes forward-looking information or forward-looking statements within the meaning of Canadian and U.S. securities laws regarding Satellos and its business, which may include, but are not limited to, statements with respect to the anticipated benefits of modulating stem cell polarity; its prospective impact on Duchenne patients and muscle regeneration generally; projected benefits of Satellos’ therapeutic approach, including small molecule drug candidates; Satellos’ technologies and drug development plans; the timeline to commence clinical trial testing in humans; the planned advancement of Satellos research and development; and the Company’s priorities and anticipated achievement of milestones and evaluation plans for drug molecules. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “progress”, “aimed”, “plan”, “expect”, “intend”, “anticipate”, “estimate”, “believe”, “hope”, “objective”, “potentially”, “possibly”, “ongoing efforts”, “develop”, “pioneering”, “groundbreaking”, “milestone”, “further”, “prospect” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks relating to the pharmaceutical and bioscience industry, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally. Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
VitalHub Grows Revenue to $24,664,593 for Fiscal 2021, an increase of 79% from Fiscal 2020
Read More

VitalHub Grows Revenue to $24,664,593 for Fiscal 2021, an increase of 79% from Fiscal 2020

Author of the article: TORONTO, March 29, 2022 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) announced today it has filed its Consolidated Financial Statements and Management’s Discussion and Analysis report for the year ended December 31, 2021, with the Canadian securities authorities. These documents may be viewed under the Company’s profile…
Ukraine c.bank keeps key rate unchanged at 25% as war rages on
Read More

Ukraine c.bank keeps key rate unchanged at 25% as war rages on

Author of the article: KYIV — Ukraine’s central bank kept its main interest rate unchanged at 25% on Thursday, saying that inflationary pressure remained high and that an extended full-scale war with Russia was the key economic risk. In a statement, the central bank said inflation had been slightly slower than its earlier forecast and…
Qatar tells UK judge it wants Airbus A321 jets or damages
Read More

Qatar tells UK judge it wants Airbus A321 jets or damages

Author of the article: PARIS — Qatar Airways has asked a UK court to reinstate an order for 50 Airbus A321neo passenger jets that the European planemaker revoked as part of a bitter dispute over the partial grounding of larger A350s, a court filing showed on Friday. Failing that, the Gulf carrier is asking a…
Indonesia’s coal supply crunch over, minister tells local media
Read More

Indonesia’s coal supply crunch over, minister tells local media

Author of the article: JAKARTA — Indonesia’s power emergency, which has triggered a coal export ban rocking global energy markets, is over and the government is reviewing a new formula for its mandatory domestic sales policy, a senior cabinet minister told local media on Friday. The world’s biggest thermal coal exporter suspended coal exports on…